What is Pembrolizumab?
Pembrolizumab is a type of immunotherapy drug that is used to treat cancer. It is also known by its brand name, Keytruda.
Pembrolizumab works by blocking a protein called PD-1 (programmed cell death protein 1) that is found on the surface of certain immune cells. PD-1 normally helps to regulate the immune system by preventing it from attacking healthy cells in the body. However, some cancer cells can also produce proteins that interact with PD-1 to evade the immune system and grow unchecked.
Download Report Sample- https://www.alliedmarketresearch.com/request-toc-and-sample/13950
By blocking PD-1, pembrolizumab helps to activate the immune system to attack and destroy cancer cells. It is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, bladder cancer, and Hodgkin lymphoma.
Pembrolizumab is typically administered as an intravenous infusion in a hospital or clinic setting. Like all medications, it can cause side effects, which can range from mild to severe. Common side effects include fatigue, nausea, diarrhea, and skin rash. More serious side effects can include immune-related adverse events, such as inflammation of the lungs, liver, or colon. As with all medications, it is important to talk to your doctor about the potential benefits and risks of pembrolizumab.
Pre-book- https://www.alliedmarketresearch.com/checkout-final/2b517d6a6cf4dac51379e19a3fe8946a
What is Pembrolizumab Market?
The market for pembrolizumab has been growing rapidly in recent years due to the drug’s effectiveness in treating certain types of cancer and its expanding indications. Pembrolizumab is developed and marketed by Merck & Co. and was first approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of advanced melanoma.
Since then, pembrolizumab has received additional approvals for the treatment of other types of cancer, including non-small cell lung cancer, head and neck cancer, bladder cancer, and Hodgkin lymphoma. The drug is also being studied in clinical trials for the treatment of various other cancers.
Do Inquiry before buying – https://www.alliedmarketresearch.com/purchase-enquiry/13950
However, the high cost of pembrolizumab and other immunotherapy drugs has been a concern for many patients and healthcare providers. In some countries, including the United States, the cost of treatment with pembrolizumab can exceed $100,000 per year. This has led to calls for increased access to affordable cancer treatments, particularly in low- and middle-income countries where the burden of cancer is highest.
However, despite the growth of the market, several factors, such as the high cost of Pembrolizumab and other biologic drugs, the lack of awareness about autoimmune diseases in some regions, and the availability of alternative treatments, may act as a barrier to the growth of the market.
Know More– https://www.alliedmarketresearch.com/pembrolizumab-market-A13581